![\"\"](\"https:\/\/www.pm360online.com\/wp-content\/uploads\/2022\/08\/BPeterson-Headshot-1.jpg\")
<\/a>Brian Peterson<\/em><\/strong> joins the full-service healthcare marketing agency to fill the newly created position of Chief Digital Officer. As such, he will be responsible for providing Greater Than One clients with transformative digital solutions through the agency\u2019s Capability Convergence model, a solution designed to leverage communications, media, and technology to build robust health ecosystems for clients and their customers.<\/p>\nPeterson commented on his appointment, \u201cI\u2019m excited to work with what is already a well-orchestrated team now in place at Greater Than One. An especially appealing factor in joining the agency was that it\u2019s wholly independent, which will allow me to develop and integrate a customized model that can be scaled up or down for each client.\u201d Previously, Peterson served in tech leadership roles at healthcare companies such as GeneDx, a clinical genomics and rare disease company.<\/p>\n
Adagio Therapeutics<\/h3>\n
The company\u2019s previous Chief Operating Officer and interim CEO, David Hering<\/em><\/strong>, is now permanently claiming the title after four months in the position. Hering will continue leading the biotech as it shoots for FDA authorization for its COVID-19 monoclonal antibody, ADG20. Before joining Adagio, Hering was head of Pfizer\u2019s mRNA global franchise where he helped launch the COVID-19 vaccine as President of North America.<\/p>\nBioXcel Therapeutics<\/h3>\n
Michael P. Miller <\/em><\/strong>has joined the Board of Directors for BioXcel, a commercial-stage biopharma company utilizing AI to develop medicines in neuroscience and immuno-oncology. Miller brings nearly 40 years of strategic leadership and commercial growth experience in the pharmaceutical industry, where he most recently served as Executive Vice President, U.S. Commercial at Jazz Pharmaceuticals.<\/p>\nCVS Health<\/h3>\n
Tilak Mandadi<\/em><\/strong> is joining CVS as an Executive Vice President and in the newly created role of Chief Data, Digital, and Technology. He leaves MGM Resorts where he served as Chief Strategy, Innovation, and Technology Officer. Mandadi will now lead the healthcare company\u2019s strategy around data and digital, focusing on digital-led, consumer-focused services and experiences.<\/p>\nElevar Therapeutics<\/h3>\n
The biopharma dedicated to elevating treatment experiences and outcomes for patients with limited therapeutic options has expanded its executive team with the appointment of Jan M. Van Tornout, MD, MSc<\/em><\/strong>, as Chief Medical Officer, and Gordon Schooley, PhD<\/em><\/strong>, as Chief Regulatory Officer. Dr. Tornout comes to Elevar with 25 years of experience, most recently serving as Chief Medical Officer of biotechnology company Tyme Technologies, Inc. Dr. Schooley is a global regulatory leader with more than 30 years of drug development experience, most recently serving as Chief Regulatory Officer for BeyondSpring Pharmaceuticals Inc. Both hires will help the company navigate rollouts of their pipeline to help fill unmet needs for patients.<\/p>\nepocrates<\/h3>\n
The athenahealth, Inc. company that delivers digital clinical decision support to prescribers has expanded its leadership team with Andrew Johnson<\/em><\/strong> to serve as the new Executive Director, Commercial Strategy, and Bridget Seay<\/em><\/strong> to serve as Executive Director, Customer Experience & Commercial Consulting. With his 15 years of sales and leadership experience, Johnson will oversee the epocrates sales team supporting the team leads and driving commercial execution for the business. Seay will lead the solutions design and account management functions while focusing on epocrates\u2019 evolution to a customer success organization. Both hires join as epocrates accelerates growth into new and existing markets, offering consultative services driven by best-in-class market intelligence to help clients achieve campaign goals and enhance clinical engagement.<\/p>\nMagellan Health<\/h3>\n
Derrick Duke<\/em><\/strong> is taking over as Chief Executive Officer of Magellan Health, a company focused on specialty areas of healthcare and accessing better health through technology. Duke joined the company in 2020 as Chief Risk Officer and will now be responsible for its strategic direction and overall growth, as well as the development and operational execution of the company\u2019s business strategy.<\/p>\nPOCN<\/h3>\n
The world\u2019s largest NP\/PA network hired Allison Bagin Kenah<\/em><\/strong> as its new Senior Vice President of Community Strategy and Network Growth. She is trusted to support new and existing industry partnerships, and engage with the growing NP and PA audience. A healthcare program management, marketing, and customer engagement experience guru, Kenah will expand POCN\u2019s growing network.<\/p>\nTruepill<\/h3>\n
The digital platform connecting telehealth, diagnostics, and pharmacy infrastructure to transform consumer healthcare named Paul Greenall<\/em><\/strong> its first Chief Business Officer. He will oversee global operations and lead Truepill\u2019s business strategy, operational partnerships, and joint ventures. Greenall previously served as Chief Strategy Officer at Prophet, where he oversaw growth strategy, planning, M&A, partnerships, and internal operations.<\/p>\nVaccentis AG<\/h3>\n
The Swiss biopharma appointed Martin Munte<\/em><\/strong>, previous executive powerhouse at Amgen, AstraZeneca, and Roche, as its new Chief Executive Officer. Boasting expertise as a leader in general management, sales and marketing, policy, access, regulatory, and business development, Munte joins Vaccentis as it grows its business and furthers its pipeline of patient-specific medicines for recovery from chronic and malignant diseases.<\/p>\nViridian Therapeutics<\/h3>\n
Carrie Melvin<\/em><\/strong> will be filling the newly created position of Chief Operating Officer for the underserved disease focused biotech company. In her 20 years of experience, Melvin has led worldwide clinical development operations in oncology and rare diseases. She will now support product development and approval for Viridian\u2019s thyroid eye disease treatments, VRDN-001 and VRDN-002.<\/p>\n","protected":false},"excerpt":{"rendered":"Inozyme Pharma Names New Chief Medical Officer The rare disease focused biopharma announced the appointment of Kurt Gunter, MD, as …<\/p>\n","protected":false},"author":70017,"featured_media":775737,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[87704,45,11991,88426],"tags":[88457,88456,56048,88455,67821,61482,80584,88458,88454,86427,231,88090,88453,88452],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/775736"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/70017"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=775736"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/775736\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media\/775737"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=775736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=775736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=775736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"https:\/\/www.pm360online.com\/wp-content\/uploads\/2022\/08\/gunter-2.jpg\")
<\/a>The rare disease focused biopharma announced the appointment of Kurt Gunter, MD<\/em><\/strong>, as the new Chief Medical Officer. Dr. Gunter comes to Inozyme with over 30 years of experience, most recently serving as CMO, Cell Therapy, and Regulatory Affairs at Athenex. \u201cIt is a pleasure to welcome Kurt to the Inozyme team to lead Inozyme\u2019s clinical development and regulatory strategy,\u201d stated Axel Bolte, MSc, MBA, Inozyme\u2019s Co-Founder, President, and Chief Executive Officer.<\/p>\n